Journals / Turkish Journal of Biology / 2014 / Cilt: 38 - Sayı: 6

Cytotoxic and apoptotic effects of ceranib-2 offering potential for a new antineoplastic agent in the treatment of cancer cells

Pages
916–921
Publication Date
2014-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results indicate that in vitro fibrocarcinomas have the potential to undergo apoptotic death when influenced by the antigrowth behaviour of ceranib-2.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fibrocarcinomas are malignant tumours that originate in mesenchymal cells.
📊
Key Findings & Data:Ceramidase inhibitors, such as ceranib-2, have demonstrated capacity to interfere with cellular DNA functionality, initiating apoptosis in many cancer cell lines.
💡
Conclusion & Impact:The results indicate that in vitro fibrocarcinomas have the potential to undergo apoptotic death when influenced by the antigrowth behaviour of ceranib-2.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ceramidase inhibitor · ceranib-2 · cancer treatment

Abstract

Fibrocarcinomas are malignant tumours that originate in mesenchymal cells. The tumours typically form in the presence of connective tissue and are of key consideration when assessing research priorities for future healthcare management. Ceramidase inhibitors, such as ceranib-2, have demonstrated capacity to interfere with cellular DNA functionality, initiating apoptosis in many cancer cell lines. The enzyme ceramidase can regulate cellular levels of sphingosine and sphingosine-1-phosphate by controlling hydrolysis of ceramide. The present study investigates the antigrowth effects of ceranib-2 on mouse embryonic fibroblast cells (NIH/3T3 normal cell line) and rat embryonic fibroblast cells (5RP7 cancer cell line). Research was conducted using colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, confocal microscopy, and transmission electron microscopy. The results indicate that in vitro fibrocarcinomas have the potential to undergo apoptotic death when influenced by the antigrowth behaviour of ceranib-2. This is true even of cells exposed only to minimal doses of ceranib-2. Indicators of apoptotic death, specifically presentation of a pyknotic nucleus, were observed by confocal micrographs in treated cells double-stained with acridine orange and Alexa Fluor-488 Phalloidin. It is theorised that ceranib-2 will function in accordance with the antiproliferative activity of other acid ceramidases, ultimately resulting in the molecule's classification as a new antitumour agent.

Özet

Fibrocarcinomas are malignant tumours that originate in mesenchymal cells. The tumours typically form in the presence of connective tissue and are of key consideration when assessing research priorities for future healthcare management. Ceramidase inhibitors, such as ceranib-2, have demonstrated capacity to interfere with cellular DNA functionality, initiating apoptosis in many cancer cell lines. The enzyme ceramidase can regulate cellular levels of sphingosine and sphingosine-1-phosphate by controlling hydrolysis of ceramide. The present study investigates the antigrowth effects of ceranib-2 on mouse embryonic fibroblast cells (NIH/3T3 normal cell line) and rat embryonic fibroblast cells (5RP7 cancer cell line). Research was conducted using colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, confocal microscopy, and transmission electron microscopy. The results indicate that in vitro fibrocarcinomas have the potential to undergo apoptotic death when influenced by the antigrowth behaviour of ceranib-2. This is true even of cells exposed only to minimal doses of ceranib-2. Indicators of apoptotic death, specifically presentation of a pyknotic nucleus, were observed by confocal micrographs in treated cells double-stained with acridine orange and Alexa Fluor-488 Phalloidin. It is theorised that ceranib-2 will function in accordance with the antiproliferative activity of other acid ceramidases, ultimately resulting in the molecule's classification as a new antitumour agent.

🔖

Cite This Article

VEJSELOVA, D., KUTLU, H. M., KUŞ, G., KABADERE, S., UYAR, R. (2014). Cytotoxic and apoptotic effects of ceranib-2 offering potential for a new antineoplastic agent in the treatment of cancer cells. Turkish Journal of Biology, Cilt: 38 - Sayı: 6, 916–921. https://ajindex.com/articles/181620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nzawa Y (2006). High expression of sphingosine kinase 1 and SIP receptors in chemotherapy resistant prostate cancer PC3 cells and their camptothecin induced upregulation. Biochem Bioph Res Co 342: 1284–1290.
  2. Beckham TH, Elojemy S, Cheng JC, Turner LS, Hoffman S, Norris JS, Liu X (2010). Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets 14: 529–539.
  3. Canals D, Perry DM, Jenkins RW, Hannun YA (2011). Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 163: 694–712.
  4. Chalfant CE, Spiegel S (2005). Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 118: 4605–4622.
  5. Chen LC, Lin CF, Chang WT, Huang WC, Teng CF, Lin YS (2008). Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein- mediated pathway. Blood 111: 4365–4374.
  6. Draper JM, Xia Z, Smith RA, Zhuang Y, Wang W, Smith CD (2011). Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther 10: 2052–2061.
  7. Hofmann K, Tomiuk S, Wolff G, Stoffel W (2000). Cloning and characterization of the mammalian brain-specific, Mg2- dependent neutral sphingomyelinase. P Natl Acad Sci U S A 97: 5895–5900.
  8. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflaceker A, Bielawski J, Hannun YA, Obeid LM (2009). Role of sphingosine kinase in colon carcinogenesis. FASEB J 23: 405–414.
  9. Koch J, Gartner S, Li CM, Quintern LE, Bernardo K, Levran O, Schnabel D, Desnick RJ, Schuchman EH, Sandhoff K (1996). Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber disease. J Biol Chem 271: 33110–33115.
  10. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S (1998). Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 273: 23722–23728.
  11. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T, Spiegel S (2000). Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275: 19513–19520.
  12. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ et al. (2000). Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951–961. Nava